Related Experiment Video

Updated: Jun 12, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Recent progess in phosphoinositide 3-kinases: oncogenic properties and prognostic and therapeutic implications

Guojun Wu1

  • 1Barbara Ann Karmanos Cancer Institute, Department of Pathology, Wayne State University, HWCRC, Room 840.2, 4100 John R, Detroit, MI 48201, USA. wugu@karmanos.org

Current Protein & Peptide Science
|May 25, 2010
PubMed

Insights

Phosphatidylinositol 3-kinases (PI3Ks), particularly PIK3CA mutations, are key drivers in human cancers. This review explores their oncogenic properties and therapeutic potential.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Phosphatidylinositol 3-kinases (PI3Ks) regulate critical cellular functions like proliferation and survival.
  • Genetic alterations, including amplification and mutations, frequently affect PI3Ks in human cancers.
  • PIK3CA mutations are common in various cancers, highlighting PI3Ks as therapeutic targets.

Purpose of the Study:

  • To review the transformation capability and oncogenic properties of PIK3CA mutations in human cancers.
  • To discuss the association of PIK3CA mutations with genetic markers and their prognostic value.
  • To explore PI3K-targeted therapies and combination strategies for cancer treatment.

Main Methods:

  • Literature review of experimental evidence on PIK3CA mutations.
  • Analysis of genetic alterations and their correlation with cancer development.
  • Evaluation of PI3K-targeted and combinational therapies in clinical applications.

Main Results:

  • PIK3CA mutations exhibit significant transformation capability and oncogenic properties.
  • Specific PIK3CA mutations are linked to other genetic markers and influence cancer prognosis.
  • PI3Ks represent promising targets for novel cancer therapies.

Conclusions:

  • PIK3CA mutations are crucial in cancer pathogenesis and serve as biomarkers.
  • Targeted and combinational therapies against PI3Ks offer therapeutic opportunities.
  • Overcoming challenges in clinical application is essential for effective PI3K-targeted cancer treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...